Impact of lecture on knowledge of IM residents in diagnosing and managing CRS and ICANS.

e23313 Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will become more prevalent in the outpatient setting as immunomodulatory drugs like chimeric antigen receptor T-cell therapy (CAR-T) and Bi-specific antibody therapy become more ubiquitous. Because of this, there is a vast need for internal medicine (IM) physicians to be aware of this. Methods: Our project entailed educational lectures for IM physicians at multiple hospitals throughout the state of Michigan in a community and academic setting. Thirty-five participants completed paired pre- and post-intervention surveys after a 1-hour educational lecture. These responses were then analyzed using a paired T-test analysis. Results: Our survey demonstrated an increase from 83% to 97% in knowledge of diagnosing CRS/ICANS and a corresponding increase from 73% to 97% in knowledge about selecting the correct treatment for CRS/ICANS. A composite toxicity confidence score (average of CRS and ICANS ratings) increased from 1.67 pre-intervention to 3.50 post-intervention, corresponding to a mean improvement of 1.83 points. Improvement was observed in nearly all participants, demonstrating a large and highly consistent effect of the educational intervention. Individually, both CRS and ICANS domains showed highly statistically significant improvements (both p < 10⁻⁹). Conclusions: Our project shows that lecture-based education on this topic in the era of emerging immune-based therapy shows robust improvement in recognition and treatment of CRS and ICANS. This can be modeled and upscaled for distribution to other disciplines, states, and institutions throughout the United States already utilizing CAR-T and bispecific antibodies.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e23313
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of lecture on knowledge of IM residents in diagnosing and managing CRS and ICANS.

Craig Emmitt Cole, Stephen Caucci, Muhammad Saleem, Nicholas Dilereto
Journal of Clinical Oncology
CAR-T cell therapy research
article

Impact of lecture on knowledge of IM residents in diagnosing and managing CRS and ICANS.

Craig Emmitt Cole, Stephen Caucci, Muhammad Saleem, Nicholas Dilereto
article en

Abstract

e23313 Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will become more prevalent in the outpatient setting as immunomodulatory drugs like chimeric antigen receptor T-cell therapy (CAR-T) and Bi-specific antibody therapy become more ubiquitous. Because of this, there is a vast need for internal medicine (IM) physicians to be aware of this. Methods: Our project entailed educational lectures for IM physicians at multiple hospitals throughout the state of Michigan in a community and academic setting. Thirty-five participants completed paired pre- and post-intervention surveys after a 1-hour educational lecture. These responses were then analyzed using a paired T-test analysis. Results: Our survey demonstrated an increase from 83% to 97% in knowledge of diagnosing CRS/ICANS and a corresponding increase from 73% to 97% in knowledge about selecting the correct treatment for CRS/ICANS. A composite toxicity confidence score (average of CRS and ICANS ratings) increased from 1.67 pre-intervention to 3.50 post-intervention, corresponding to a mean improvement of 1.83 points. Improvement was observed in nearly all participants, demonstrating a large and highly consistent effect of the educational intervention. Individually, both CRS and ICANS domains showed highly statistically significant improvements (both p < 10⁻⁹). Conclusions: Our project shows that lecture-based education on this topic in the era of emerging immune-based therapy shows robust improvement in recognition and treatment of CRS and ICANS. This can be modeled and upscaled for distribution to other disciplines, states, and institutions throughout the United States already utilizing CAR-T and bispecific antibodies.

Journal of Clinical OncologyVol. 44(16_suppl)
The Barbara Ann Karmanos Cancer Institute (US), McLaren Greater Lansing (US), Michigan State University (US)
Quality Education
Openalex Percentile: Top 8%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.